CAR-T

China’s National Immigration Administration Introduces 5 New Measures to Facilitate Entry China for Foreign Nationals

China’s National Immigration Administration Introduces 5 New Measures to Facilitate Entry China for Foreign Nationals China’s National Immigration Administration has officially implemented five new measures starting from January 11th, aimed at further facilitating entry for foreign nationals. These measures aim to streamline the processes for foreign individuals engaging in business, studying, and tourism, contributing to Read More

January 12th,2024 CAR-T

Breakthrough CAR-T Cell Therapy for R/R B-Cell ALL: A Game-Changer in Chinese Medical Innovation

Breakthrough CAR-T Cell Therapy for R/R B-Cell ALL: A Game-Changer in Chinese Medical Innovation ALL- Acute Lymphoblastic Leukemia The Fourth China Hematology Development Conference – CAR-T Frontier Forum and the First CAR-T Cell Immunotherapy Summit (JCIS), held on January 5, 2024, in Tianjin.   Potential Best-in-Class: Inaticabtagene Autoleucel Redefining Long-term Outcomes for R/R B-ALL   Read More

January 11th,2024 CAR-T

Clinical Breakthrough: Chinese CAR-T – Inaticabtagene Autoleucel Revolutionizing Hematologic Cancer Therapy

“Clinical Breakthrough: Chinese CAR-T – Inaticabtagene Autoleucel Revolutionizing Hematologic Cancer Therapy” On January 5, 2024, the Fourth Chinese Hematology Development Conference was convened in Tianjin, China, concurrently hosting the CAR-T Frontier Forum and the First CAR-T Cell Immunotherapy Summit (JCIS). The focus was directed towards the latest advancements and clinical applications of Inaticabtagene Autoleucel, presenting Read More

January 10th,2024 CAR-T

Exploring Tumor Vitality: Chinese CAR-T Therapy Grants Patients Complete Remission

Exploring Tumor Vitality: Chinese CAR-T Therapy Grants Patients Complete Remission “Is it true? It’s so unbelievable!” said Chen, the “fortunate one.”   On June 22, 2021, the approval of China’s first CAR-T cell therapy product, Yescarta, marked a significant milestone in medicine. Behind this milestone lies the story of a patient named Chen, diagnosed with Read More

January 9th,2024 CAR-T

Two Years of Complete Remission(Lymphoma), CAR-T therapy has given her a new lease on life.

“Two Years of Complete Remission, CAR-T therapy has given her a new lease on life.  She Thought the Journey Was Over”   Yun is a 78-year-old patient who achieved a continuous complete remission for two and a half years despite relapsed/refractory diffuse large B-cell lymphoma. Diagnosed in 2019, after enduring six rounds of chemotherapy, she Read More

January 5th,2024 CAR-T

Breakthrough Advances in CAR-T Cell Therapy Combined with TKI for Malignant Hematologic System Tumors

Breakthrough Advances in CAR-T Cell Therapy Combined with TKI for Malignant Hematologic System Tumors At this year’s ASH conference, Professor Huang He, the director of the First Affiliated Hospital of Zhejiang University School of Medicine, presented a significant study on CAR-T cell therapy for B-ALL, marking a groundbreaking stride in the treatment of malignant hematologic Read More

January 5th,2024 CAR-T

Chinese Research Team New Treatment Shows Promise: CD7 CAR-T Cell Therapy for Relapsed/Refractory AML

Chinese Research Team New Treatment Shows Promise: CD7 CAR-T Cell Therapy for Relapsed/Refractory AML A recent clinical trial has unveiled a new prospect for treating relapsed/refractory acute myeloid leukemia (AML). The study delved into the safety and efficacy of a natural selection CD7 CAR-T cell (NS7 CAR-T cell) in treating CD7+ relapsed/refractory AML patients.   Read More

January 4th,2024 CAR-T

New Generation CAR-T Cell Therapy AT101: Phase I Clinical Trial Shows 100% Complete Remission Rate!

New Generation CAR-T Cell Therapy AT101: Phase I Clinical Trial Shows 100% Complete Remission Rate! Researchers recently released exciting news: the Phase I clinical trial of their newly developed CAR-T cell therapy, AT101, demonstrated a 100% complete remission rate among patients receiving high-dose treatment. This groundbreaking achievement was published in the latest “Molecular Cancer” journal Read More

January 3rd,2024 CAR-T

A Chinese research team has made significant advancements in the treatment of colorectal cancer, paving the way for a new milestone in the field of oncology treatment

A Chinese research team has made significant advancements in the treatment of colorectal cancer, paving the way for a new milestone in the field of oncology treatment In recent years, natural killer (NK) cell immunotherapy has gained significant attention as a promising approach for treating solid tumors and malignant tumors of the blood system. NK Read More

January 2nd,2024 CAR-T

Chinese Research: Hopes of CAR-T in Second-Line Treatment of LBCL（Lymphoma）

Diffuse Large B-cell Lymphoma （LBCL）is a heterogeneous malignant tumor of the blood system, with approximately 40% of LBCL patients experiencing relapse or developing resistance after first-line treatment, progressing to relapsed/refractory large B-cell lymphoma (R/R LBCL). In recent years, chimeric antigen receptor T-cell therapy targeting CD19 (CAR-T) has made significant breakthroughs in treating relapsed or refractory Read More

December 29th,2023 CAR-T

Breakthrough in CAR-T Therapy Achieved by Chinese Sun Yat-sen University Cancer Center

Recently, Professor Huang Huiqiang’s team at Sun Yat-sen University Affiliated Cancer Hospital achieved significant progress in a lymphoma patient who relapsed after five lines of chemotherapy. Utilizing CAR-T therapy, the patient has experienced complete remission for over two years, making them one of the patients in China with the longest survival post-CAR-T treatment. Lymphoma, one Read More

December 28th,2023 CAR-T

A significant breakthrough in Chinese solid tumor CAR-T therapy, resulting in complete remission for pancreatic cancer patients.

Chinese pharmaceutical company SciCoMed announced a significant breakthrough in treating metastatic pancreatic cancer with its independently developed CAR-T cell therapy targeting Claudin18.2, known as CT041. Pancreatic cancer, often termed the “king of cancers,” presents a significant challenge with low survival rates. However, CT041’s two representative cases have garnered attention: two patients with refractory pancreatic cancer, Read More

December 27th,2023 CAR-T